Boston, MA -- (SBWIRE) -- 08/22/2012 -- The report presents and analyzes exclusive survey data from 126 industry executives on industry incentives, commercial environment, and partnership plans. Each country's macroeconomic, pricing and reimbursement, and healthcare environment is described and compared. An attractiveness index allowing comparison of the five countries along four dimensions is also presented.
- Forecast pharmaceutical sales for five key Middle East countries to 2017.
- Gain insights into the relative merits of Middle Eastern pharma markets from a survey of 126 executives.
- Learn about regional variations in IP protection, infrastructure, and disease burden.
- Evaluate pricing and reimbursement environments across the region.
- Assess each of the five countries using the Scrip Insights attractiveness index.
Looking at sales forecasts for 2012, Egyptian sales are estimated at $3.9bn, followed by Iran ($2.9bn), Saudi Arabia ($2.3bn), Israel ($1.5bn), and the UAE ($1.3bn). On a per capita basis, Israel and UAE lead the way, due to their comparatively small populations.
View Full Report Details and Table of Contents
The Scrip Insights' survey of pharmaceutical industry insiders found that UAE ranked highly in encouraging foreign investment, while Iran lagged. For encouraging innovation, 88% of respondents thought that Israel had put in place enough initiatives to encourage innovation in the domestic biopharma industry.
Compared with 2012, by 2017 the market for pharmaceuticals in UAE is forecast to have risen the most in percentage terms among the five countries, by 115%. The UAE topped the Scrip Insights attractiveness index due to its high growth prospects and government incentives for overseas investment.
Reasons to Get this Report
- How do Egpyt, Iran, Saudi Arabia, Israel, and the UAE compare in terms of healthcare infrastructure, and government incentives for pharma companies?
- Which countries have the greatest disease burden?
- How do drug prices and per capita pharmaceutical spending vary across the region?
- Which countries have the greatest incentives for innovation?
- How are political events shaping the market environments across the region?
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- The Outlook for Pharmaceuticals in the Middle East and North Africa
- Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force
- Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies
- Industry Dynamics, Growth, Threats & Opportunities in the Pharmaceutical Industry - 2012-2013 : Survey Intelligence
- Emerging Pharmaceutical Market in China - Forecast to Become The World's Third-Largest Pharmaceutical Market By 2013
- Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
- Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
- Demand in Emerging Markets in the Pharmaceutical Industry - 2012-2013 : Survey Snapshot
- Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
- Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies